The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes

Documenti analoghi

• Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice
  di: Paas-Rozner, Miri, et al.
  Pubblicazione: (2000)
• A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4(+) T cells
  di: Paas-Rozner, Miri, et al.
  Pubblicazione: (2003)
• The role of CD8(+)CD28(−) regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand
  di: Ben-David, Hava, et al.
  Pubblicazione: (2007)
• A 50-kDa ERK-like protein is up-regulated by a dual altered peptide ligand that suppresses myasthenia gravis-associated responses
  di: Ben-David, Hava, et al.
  Pubblicazione: (2006)
• Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity induced by myasthenogenic T cell epitopes
  di: Faber-Elmann, Anat, et al.
  Pubblicazione: (1998)